Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"PINOTBIO","sponsor":"Lotte Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LOTTE BIOLOGICS Announces Investment in PINOT BIO, ADC Platform Development Pioneer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by PINOTBIO

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The investment will facilitate the creation of a cross-industry synergistic environment for the development and production of ADC platforms including, PINOT-ADC™, a next-generation ADC anti-cancer drug platform developing PBX-001 (sacituzumab), targeting solid cancer Trop2.

            Lead Product(s): Sacituzumab Govitecan

            Therapeutic Area: Oncology Product Name: PBX-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lotte Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing April 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY